Medicenna Therapeutics Corp
Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. It develops bizaxofusp, an interleukin- 4 (IL-4) targeted therapy for the treatment of recurrent glioblastoma. The company also develops MDNA11, a long-acting interleuk… Read more
Medicenna Therapeutics Corp (MDNAF) - Total Assets
Latest total assets as of September 2025: $18.04 Million USD
Based on the latest financial reports, Medicenna Therapeutics Corp (MDNAF) holds total assets worth $18.04 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Medicenna Therapeutics Corp - Total Assets Trend (2014–2025)
This chart illustrates how Medicenna Therapeutics Corp’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Medicenna Therapeutics Corp - Asset Composition Analysis
Current Asset Composition (March 2025)
Medicenna Therapeutics Corp's total assets of $18.04 Million consist of 99.3% current assets and 0.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 87.5% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2014–2025)
This chart illustrates how Medicenna Therapeutics Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Medicenna Therapeutics Corp's current assets represent 99.3% of total assets in 2025, a decrease from 100.0% in 2014.
- Cash Position: Cash and equivalents constituted 87.5% of total assets in 2025, up from 0.7% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2014.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Medicenna Therapeutics Corp Competitors by Total Assets
Key competitors of Medicenna Therapeutics Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Medicenna Therapeutics Corp - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Medicenna Therapeutics Corp generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Medicenna Therapeutics Corp is currently not profitable relative to its asset base.
Medicenna Therapeutics Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.01 | 11.40 | 22.83 |
| Quick Ratio | 4.01 | 11.40 | 22.83 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $13.41 Million | $ 29.82 Million | $ 35.87 Million |
Medicenna Therapeutics Corp - Advanced Valuation Insights
This section examines the relationship between Medicenna Therapeutics Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.71 |
| Latest Market Cap to Assets Ratio | 1.48 |
| Asset Growth Rate (YoY) | 48.3% |
| Total Assets | $28.38 Million |
| Market Capitalization | $42.11 Million USD |
Valuation Analysis
Above Book Valuation: The market values Medicenna Therapeutics Corp's assets above their book value (1.48 x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Medicenna Therapeutics Corp's assets grew by 48.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Medicenna Therapeutics Corp (2014–2025)
The table below shows the annual total assets of Medicenna Therapeutics Corp from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | $28.38 Million | +48.33% |
| 2024-03-31 | $19.13 Million | -47.50% |
| 2023-03-31 | $36.45 Million | +55.38% |
| 2022-03-31 | $23.46 Million | -44.49% |
| 2021-03-31 | $42.25 Million | +11.20% |
| 2020-03-31 | $38.00 Million | +632.47% |
| 2019-03-31 | $5.19 Million | +18.58% |
| 2018-03-31 | $4.37 Million | -69.80% |
| 2017-03-31 | $14.48 Million | +151.66% |
| 2016-03-31 | $5.76 Million | +2011.45% |
| 2015-03-31 | $272.56K | -51.57% |
| 2014-03-31 | $562.85K | -- |